An ER-directed gelsolin nanobody targets the first step in amyloid formation in a gelsolin amyloidosis mouse model

Human Molecular Genetics

Volumn 24, Issue 9, 2015, Pages 2492-2507

  Van Overbeke, Wouter ^a   Wongsantichon, Jantana ^b   Everaert, Inge ^a   Verhelle, Adriaan ^a   Zwaenepoel, Olivier ^a   Loonchanta, Anantasak ^c   Burtnick, Leslie D ^c   De Ganck, Ariane ^a,g   Hochepied, Tino ^a   Haigh, Jody ^a,e,f   Cuvelier, Claude ^a   Derave, Wim ^a   Robinson, Robert C ^b,d   Gettemans, Jan ^a  

^a GHENT UNIVERSITY   (Belgium)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e Unit for Medical Biotechnology Inflammation Research Centre (IRC) VIB UGent   (Belgium)

^f MONASH UNIVERSITY   (Australia)

^g Biogazelle NV   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; CHAPERONE; FURIN; GELSOLIN; GELSOLIN NANOBODY 11; MONOCLONAL ANTIBODY; NANOBODY; PROTECTIVE AGENT; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG; AMYLOID; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTISENSE VECTOR; ARTICLE; CONTROLLED STUDY; CROSS BREEDING; CRYSTAL STRUCTURE; DRUG EFFICACY; DRUG TARGETING; EMBRYO; ENDOPLASMIC RETICULUM; FAMILIAL AMYLOIDOSIS; FEMALE; GENE INSERTION; GENOME; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; MOUSE; MUSCLE CONTRACTILITY; MUTANT; NONHUMAN; NONVIRAL GENE THERAPY; PLASMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; TRANS GOLGI NETWORK; TRANSGENIC MOUSE; X RAY CRYSTALLOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HEK293 CELL LINE; METABOLISM; MUSCLE CONTRACTION; MUTATION; PATHOPHYSIOLOGY; PROTEIN CONFORMATION; SKELETAL MUSCLE;

AMYLOID; AMYLOIDOSIS, FAMILIAL; ANIMALS; DISEASE MODELS, ANIMAL; ENDOPLASMIC RETICULUM; FURIN; GELSOLIN; GENE EXPRESSION; HEK293 CELLS; HUMANS; MICE; MICE, TRANSGENIC; MUSCLE CONTRACTION; MUSCLE, SKELETAL; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEOLYSIS; SINGLE-DOMAIN ANTIBODIES; TRANS-GOLGI NETWORK;

EID: 84941992345     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv010     Document Type: Article

References (53)

1. Harrison, R.S., Sharpe, P.C., Singh, Y. and Fairlie, D.P. (2007) Amyloid peptides and proteins in review. Rev. Physiol. Biochem. Pharmacol., 159, 1-77.
2. Kirkitadze, M.D., Condron, M.M. and Teplow, D.B. (2001) Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis. J. Mol. Biol., 312, 1103-1119.
3. Walsh, D.M., Hartley, D.M., Kusumoto, Y., Fezoui, Y., Condron, M.M., Lomakin, A., Benedek, G.B., Selkoe, D.J. and Teplow, D.B. (1999) Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem., 274, 25945-25952.
4. de la Chapelle, A., Tolvanen, R., Boysen, G., Santavy, J., Bleeker-Wagemakers, L., Maury, C.P. and Kere, J. (1992) Gelsolin-derived familial amyloidosis caused by asparagine or tyrosine substitution for aspartic acid at residue 187. Nat. Genet., 2, 157-160.
5. Meretoja, J. (1973) Genetic aspects of familial amyloidosis with corneal lattice dystrophy and cranial neuropathy. Clin. Genet., 4, 173-185.
6. Janmey, P.A., Chaponnier, C., Lind, S.E., Zaner, K.S., Stossel, T. P. and Yin, H.L. (1985) Interactions of gelsolin and gelsolinactin complexes with actin. Effects of calciumon actin nucleation, filament severing, and end blocking. Biochemistry, 24, 3714-3723.
7. Nag, S., Larsson, M., Robinson, R.C. and Burtnick, L.D. (2013) Gelsolin: the tail of a molecular gymnast. Cytoskeleton, 70, 360-384.
8. Nag, S., Ma, Q., Wang, H., Chumnarnsilpa, S., Lee, W.L., Larsson, M., Kannan, B., Hernandez-Valladares, M., Burtnick, L.D. and Robinson, R.C. (2009) Ca2+ binding by domain 2 plays a critical role in the activation and stabilization of gelsolin. Proc. Natl Acad. Sci. USA, 106, 13713-13718.
9. Isaacson, R.L., Weeds, A.G. and Fersht, A.R. (1999) Equilibria and kinetics of folding of gelsolin domain 2 and mutants involved in familial amyloidosis-Finnish type. Proc. Natl Acad. Sci. USA, 96, 11247-11252.
10. Burtnick, L.D., Urosev, D., Irobi, E., Narayan, K. and Robinson, R.C. (2004) Structure of the N-terminal half of gelsolin bound to actin: roles in severing, apoptosis and FAF. EMBO J., 23, 2713-2722.
11. Chen, C.D., Huff, M.E., Matteson, J., Page, L., Phillips, R., Kelly, J.W. and Balch, W.E. (2001) Furin initiates gelsolin familial amyloidosis in the Golgi through a defect in Ca(2+) stabilization. EMBO J., 20, 6277-6287.
12. Page, L.J., Suk, J.Y., Huff, M.E., Lim, H.J., Venable, J., Yates, J., Kelly, J.W. and Balch, W.E. (2005) Metalloendoprotease cleavage triggers gelsolin amyloidogenesis. EMBO J., 24, 4124-4132.
13. Kiuru, S. (1998) Gelsolin-related familial amyloidosis, Finnish type (FAF), and its variants found worldwide. Amyloid, 5, 55-66.
14. Paunio, T., Kangas, H., Kalkkinen, N., Haltia, M., Palo, J. and Peltonen, L. (1994) Toward understanding the pathogenic mechanisms in gelsolin-related amyloidosis: in vitro expression reveals an abnormal gelsolin fragment. Hum. Mol. Genet., 3, 2223-2229.
15. Kangas, H., Seidah, N.G. and Paunio, T. (2002) Role of proprotein convertases in the pathogenic processing of the amyloidosis-associated form of secretory gelsolin. Amyloid, 9, 83-87.
16. Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hamers, C., Songa, E.B., Bendahman, N. and Hamers, R. (1993) Naturally occurring antibodies devoid of light chains. Nature, 363, 446-448.
17. Delanote, V., Vanloo, B., Catillon, M., Friederich, E., Vandekerckhove, J. and Gettemans, J. (2010) An alpaca single-domain antibody blocks filopodia formation by obstructing L-plastin-mediated F-actin bundling. FASEB J., 24, 105-118.
18. Van den Abbeele, A., De Clercq, S., De Ganck, A., De Corte, V., Van Loo, B., Soror, S.H., Srinivasan, V., Steyaert, J., Vandekerckhove, J. and Gettemans, J. (2010) A llama-derived gelsolin single-domain antibody blocks gelsolin-G-actin interaction. Cell. Mol. Life Sci., 67, 1519-1535.
19. Van Audenhove, I., Van Impe, K., Ruano-Gallego, D., De Clercq, S., De Muynck, K., Vanloo, B., Verstraete, H., Fernandez, L.A. and Gettemans, J. (2013) Mapping cytoskeletal protein function in cells by means of nanobodies. Cytoskeleton, 70, 604-622.
20. Van Impe, K., Bethuyne, J., Cool, S., Impens, F., Ruano-Gallego, D., De Wever, O., Vanloo, B., Van Troys, M., Lambein, K., Boucherie, C. et al. (2013) A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis. Breast Cancer Res, 15, R116.
21. Muyldermans, S. (2013) Nanobodies: natural single-domain antibodies. Ann. Rev. Biochem., 82, 775-797.
22. Van Overbeke, W., Verhelle, A., Everaert, I., Zwaenepoel, O., Vandekerckhove, J., Cuvelier, C., Derave, W. and Gettemans, J. (2014) Chaperone nanobodies protect gelsolin against MT1-MMP degradation and alleviate amyloid burden in the gelsolin amyloidosis mouse model. Mol. Ther., 22, 1768-1778.
23. Seidah, N.G., Day, R., Marcinkiewicz, M. and Chretien, M. (1998) Precursor convertases: an evolutionary ancient, cellspecific, combinatorial mechanism yielding diverse bioactive peptides and proteins. Ann. N Y Acad. Sci., 839, 9-24.
24. Molloy, S.S., Thomas, L., VanSlyke, J.K., Stenberg, P.E. and Thomas, G. (1994) Intracellular trafficking and activation of the furin proprotein convertase: localization to the TGN and recycling from the cell surface. EMBO J., 13, 18-33.
25. Molloy, S.S., Bresnahan, P.A., Leppla, S.H., Klimpel, K.R. and Thomas, G. (1992) Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. J. Biol. Chem., 267, 16396-16402.
26. Abrami, L., Fivaz, M., Decroly, E., Seidah, N.G., Jean, F., Thomas, G., Leppla, S.H., Buckley, J.T. and van der Goot, F.G. (1998) The pore-forming toxin proaerolysin is activated by furin. J. Biol. Chem., 273, 32656-32661.
27. Roebroek, A.J., Umans, L., Pauli, I.G., Robertson, E.J., van Leuven, F., Van de Ven, W.J. and Constam, D.B. (1998) Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase Furin. Development, 125, 4863-4876.
28. Page, L.J., Suk, J.Y., Bazhenova, L., Fleming, S.M., Wood, M., Jiang, Y., Guo, L.T., Mizisin, A.P., Kisilevsky, R., Shelton, G.D. et al. (2009) Secretion of amyloidogenic gelsolin progressively compromises protein homeostasis leading to the intracellular aggregation of proteins. Proc. Natl Acad. Sci. USA, 106, 11125-11130.
29. Burtnick, L.D., Koepf, E.K., Grimes, J., Jones, E.Y., Stuart, D.I., McLaughlin, P.J. and Robinson, R.C. (1997) The crystal structure of plasma gelsolin: implications for actin severing, capping, and nucleation. Cell, 90, 661-670.
30. Thomas, G. (2002) Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat. Rev. Mol. Cell Biol., 3, 753-766.
31. Zaias, J., Mineau, M., Cray, C., Yoon, D. and Altman, N.H. (2009) Reference values for serum proteins of common laboratory rodent strains. J. Am Assoc. Lab. Anim. Sci., 48, 387-390.
32. Wolff, S., Weissman, J.S. and Dillin, A. (2014) Differential scales of protein quality control. Cell, 157, 52-64.
33. Guerrero-Munoz, M.J., Castillo-Carranza, D.L. and Kayed, R. (2014) Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. Biochem. Pharmacol., 88, 468-478.
34. Herva, M.E., Zibaee, S., Fraser, G., Barker, R.A., Goedert, M. and Spillantini, M.G. (2014) Anti-amyloid compounds inhibit alpha-synuclein aggregation induced by protein misfolding cyclic amplification (PMCA). J. Biol. Chem., 289, 11897-11905.
35. Kisilevsky, R., Ancsin, J.B., Szarek, W.A. and Petanceska, S. (2007) Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications. Amyloid, 14, 21-32.
36. Molloy, S.S., Anderson, E.D., Jean, F. and Thomas, G. (1999) Bicycling the furin pathway: from TGN localization to pathogen activation and embryogenesis. Trend. Cell Biol., 9, 28-35.
37. Anliker, B., Abel, T., Kneissl, S., Hlavaty, J., Caputi, A., Brynza, J., Schneider, I.C., Munch, R.C., Petznek, H., Kontermann, R.E. et al. (2010) Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat. Method., 7, 929-935.
38. Zinn, E. and Vandenberghe, L.H. (2014) Adeno-associated virus: fit to serve. Curr. Opin. Virol., 8, 90-97.
39. Im, G.I. (2013) Nonviral gene transfer strategies to promote bone regeneration. J. Biomed. Mat. Res. Part A, 101, 3009-3018.
40. Weeds, A.G., Gooch, J., McLaughlin, P. and Maury, C.P. (1993) Variant plasma gelsolin responsible for familial amyloidosis (Finnish type) has defective actin severing activity. FEBS Lett., 335, 119-123.
41. Maury, C.P. (1993) Homozygous familial amyloidosis, Finnish type: demonstration of glomerular gelsolin-derived amyloid and non-amyloid tubular gelsolin. Clin. Nephrol., 40, 53-56.
42. Lind, S.E., Smith, D.B., Janmey, P.A. and Stossel, T.P. (1986) Role of plasma gelsolin and the vitamin D-binding protein in clearing actin from the circulation. J. Clin. Invest., 78, 736-742.
43. Wang, D. and Gao, G. (2014) State-of-the-art human gene therapy: part I. Gene delivery technologies. Discover. Med., 18, 67-77.
44. Wang, D. and Gao, G. (2014) State-of-the-art human gene therapy: Part II. Gene therapy strategies and clinical applications. Discover. Med., 18, 151-161.
45. Van den Abbeele, A., De Corte, V., Van Impe, K., Bruyneel, E., Boucherie, C., Bracke, M., Vandekerckhove, J. and Gettemans, J. (2007) Downregulation of gelsolin family proteins counteracts cancer cell invasion in vitro. Cancer Lett., 255, 57-70.
46. Nyabi, O., Naessens, M., Haigh, K., Gembarska, A., Goossens, S., Maetens, M., De Clercq, S., Drogat, B., Haenebalcke, L., Bartunkova, S. et al. (2009) Efficient mouse transgenesis using Gateway-compatible ROSA26 locus targeting vectors and F1 hybrid ES cells. Nucleic Acids Res., 37, e55.
47. Pasquato, A., Dettin, M., Basak, A., Gambaretto, R., Tonin, L., Seidah, N.G. and Di Bello, C. (2007) Heparin enhances the furin cleavage of HIV-1 gp160 peptides. FEBS Lett., 581, 5807-5813.
48. George, S.H., Gertsenstein, M., Vintersten, K., Korets-Smith, E., Murphy, J., Stevens, M.E., Haigh, J.J. and Nagy, A. (2007) Developmental and adult phenotyping directly from mutant embryonic stem cells. Proc. Natl Acad. Sci. USA, 104, 4455-4460.
49. Brown, T. (2001) Southern blotting. Current protocols in immunology/ edited by John E. Coligan ... [et al.], Chapter 10, Unit 10 16A.
50. McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D.,Winn, M.D., Storoni, L.C. and Read, R.J. (2007) Phaser crystallographic software. J. Appl. Crystallogr., 40, 658-674.
51. Emsley, P., Lohkamp, B., Scott, W.G. and Cowtan, K. (2010) Features and development of Coot. Acta Crystallogr. Sec. D, Biol. Crystallogr., 66, 486-501.
52. Winn, M.D., Ballard, C.C., Cowtan, K.D., Dodson, E.J., Emsley, P., Evans, P.R., Keegan, R.M., Krissinel, E.B., Leslie, A.G., McCoy, A. et al. (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr. Sec. D, Biol. Crystallogr., 67, 235-242.
53. Adams, P.D., Afonine, P.V., Bunkoczi, G., Chen, V.B., Davis, I. W., Echols, N., Headd, J.J., Hung, L.W., Kapral, G.J., Grosse-Kunstleve, R.W. et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. Sec. D, Biol. Crystallogr., 66, 213-221.